Critical decisions in selecting an intravenous immunoglobulin product

Journal of Infusion Nursing

Volumn 28, Issue 6, 2005, Pages 366-374

  Gelfand, Erwin W ^a,b  

^a NATIONAL JEWISH MEDICAL AND RESEARCH CENTER   (United States)

^b UNIVERSITY OF COLORADO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIHISTAMINIC AGENT; CARIMUNE; CORTICOSTEROID; HUMAN IMMUNOGLOBULIN; IMMUNOGLOBULIN; IMMUNOGLOBULIN G; IVEEGAM EN; NONSTEROID ANTIINFLAMMATORY AGENT; PANGLOBULIN; PARACETAMOL; UNCLASSIFIED DRUG;

AGE; ASEPTIC MENINGITIS; AUTOIMMUNE DISEASE; CARDIOVASCULAR DISEASE; COUGHING; DRUG EFFICACY; DRUG HALF LIFE; DRUG INFUSION; DRUG MANUFACTURE; DRUG MEGADOSE; DRUG SAFETY; DRUG TOLERABILITY; DYSPNEA; FEVER; HEADACHE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPERVISCOSITY SYNDROME; IMMUNE DEFICIENCY; IMMUNOTHERAPY; INFLAMMATORY DISEASE; KIDNEY DISEASE; LUNG DISEASE; LUNG EDEMA; MEDICAL DECISION MAKING; MUCOCUTANEOUS LYMPH NODE SYNDROME; NAUSEA; PRIORITY JOURNAL; RASH; REVIEW; RISK FACTOR; SORE THROAT; SYNCOPE; THROMBOEMBOLISM; TREATMENT INDICATION;

EID: 28344454446     PISSN: 15331458     EISSN: None     Source Type: Journal    
DOI: 10.1097/00129804-200511000-00003     Document Type: Review

References (32)

1. Chapel HM, Dicato M, Gamm H, et al. Immunoglobulin replacement in patients with chronic lymphocytic leukemia: comparison of two dose regimens. Br J Haematol. 1994;89:209-212.
2. Kazatchkine MD, Kaveri SV. Advances in immunology: immunomodulation of autoimmune and inflammatory diseases with intravenous immune globulin. N Engl J Med. 2001;345:747-755.
3. Gelfand EW. Use of IGIV in the treatment of immune-mediated dermatologic disorders. J Invest Dermatol. 2004;9:92-96.
4. Gelfand EW, Mazer BD. Intravenous γ-globulin: an alternative treatment in severe steroid-dependent asthma. In: Hassig A, Cottier H, Kazatchkine M, Newland AD, Gelfand EW, eds. Immodulation by Intravenous Immunoglobulin. London: Parthenon; 1993:179-188.
5. World Health Organization. The use of human immunoglobulin. Report of a WHO Expert Committee. World Health Organization technical report series. 1966;327:1.
6. Durandy A, Wahn V, Petteway S, Gelfand EW. Immunoglobulin replacement therapy in primary antibody deficiency diseases: maximizing success. Int Arch Allergy Immunol. 2005;136:217-229.
7. Bonillo FA. Antibody deficiency. In: Leung DYM, Sampson HA, Geha RS, Szefler SJ, eds. Pediatric Allergy: Principles and Practice. Philadelphia: Mosby; 2003:88-98.
8. Gardulf A, Anderson V, Bjorkander J, et al. Subcutaneous immunoglobulin replacement in patients with primary antibody deficiency: safety and costs. Lancet. 1995;345:365-369.
9. van der Meche FG, van Doorn PA. The current place of high-dose immunoglobulins in the treatment of neuromuscular disorders. Muscle Nerve. 1997;20:136-147.
10. Immune Deficiency Foundation. Treatment experiences and preferences of patients with primary immune deficiency diseases: national survey, 2003. Available at: http://www.primaryimmune.org/pid/ 2003_idf_survey_complete.pdf. Accessed 2004.
11. Hetherington SV, Giebink GS. Opsonic activity of immunoglobulin prepared for intravenous use. J Lab Clin Med. 1984;104:977-986.
12. Schroeder DD, Tankersley DL, Lundblad JL. A new preparation of modified immune serum globulin (human) suitable for intravenous administration. II. Functional characterization. Vox Sang. 1981;40:383-394.
13. van Furth R, Leijh PC, Klein F. Correlation between opsonic activity for various microorganisms and composition of gammaglobulin preparations for intravenous use. J Infect Dis. 1984;149:511-517.
14. van Furth R, Braat AG, Leijh PC, Gardi A. Opsonic activity and physiochemical characteristics of intravenous immunoglobulin preparations. Vox Sang. 1987;53:70-75.
15. Givner LB. Human immunoglobulins for intravenous use: comparison of available preparations for group B streptococcal antibody levels, opsonic activity and efficacy in animal models. Pediatrics. 1990;86:955-962.
16. Centers for Disease Control and Prevention. Outbreak of hepatitis C associated with intravenous administration-United States. October 1993-June 1994. MMWR Morb Mortal Wkly Rep. 1993; 43:505-509.
17. Korneyeva M, Hotta J, Lebing W, Rosenthal RS, Franks I, Petteway SR Jr. Enveloped virus inactivation by caprylate: a robust alternative to solvent-detergent treatment. Biologicals. 2002;30:153-162.
18. Renal insufficiency and failure associated with immune globulin intravenous therapy. MMWR Morb Mortal Wkly Rep. 1999;48: 1985-1998.
19. Nydegger UW, Sturzenegger M. Adverse effects of intravenous immunoglobulin therapy. Drug Safety. 1999;21:171-185.
20. National Institutes of Health. Consensus Development Conference. Intravenous Immune Globulin: Prevention and Treatment of Diseases. Consensus statement. Bethesda, MD: Department of Health and Human Services. 1990; 8(5).
21. Friesen AD, Bowman JM, Bees WCH. Column ion exchange chromatographic production of human serum globulin for intravenous Suse. Vox Sang. 1985;48:201-212.
22. Sekul EA, Culper EJ, Dalakas MC. Aseptic meningitis associated with high-dose intravenous immunoglobulin therapy: frequency and risk factors. Ann Intern Med. 1994;121:259-262.
23. Stangel M, Hartung HP, Marx P, Gold R. Side effects of high-dose intravenous immunoglobulins. Clin Neuropharmacol. 1997; 20:385-393.
24. Anderson W, Bethea W. Renal lesions following administration of hypertonic solutions of sucrose. JAMA. 1940;114:1983-1987.
25. Schwartz SL, Johnson CB. Pinocytosis as a cause of sucrose nephrosis. Nephron. 1971;8:246-254.
26. Dalakas MC. Mechanism of action of intravenous immunoglobulin and therapeutic considerations in the treatment of autoimmune neurologic diseases. Neurology. 1998;51:S2-S8.
27. Perazella MA, Cayco AV. Acute renal failure and intravenous immune globulin: sucrose nephropathy in disguise? Am J Ther. 1998; 5:399-403.
28. Lemm G. Composition and properties of IVIG preparations that affect tolerability and therapeutic efficacy. Neurology. 2002;59: S28-S32.
29. Zhang R, Szerlip HM. Reemergence of sucrose nephropathy: acute renal failure caused by high-dose intravenous immune globulin therapy. South Med J. 2002;93:901-904.
30. Ryan ME, Webster ML, Statler JD. Adverse effects of intravenous immunoglobulin therapy. Clin Pediatr. 1996;35:23-31.
31. Dalakas MC. High-dose intravenous immunoglobulin and serum viscosity: risk of precipitating thromboembolic events. Neurology. 1994;44:223-226.
32. Roifman DM, Schroeder H, Berger M, et al. Comparison of the efficacy of IGIV-C, 10% (caprylate/chromatography) and IGIV-SD, 10% as replacement therapy in primary immune deficiency, a randomized double-blind trial. Int Immunopharmacol. 2003;3: 1325-1333.